prnewswire.com · 1 jul

Ecopetrol Group receives payment for 100% of the FEPC account receivable balance for the second quarter of 2025

BOGOTÁ, Colombia, July 1, 2026 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL) (NYSE: EC) (the "Company") hereby announces that the National Government, through Resolution 1492 dated June 30, 2026, issued by the Ministry of Finance and Public Credit ("MHCP"), recognized and ordered payment to the Ecopetrol Group in an aggregate amount of approximately COP 1 trillion, corresponding to the account receivable from the Fuel Price Stabilization Fund ("FEPC") for the second quarter of 2025.

zacks.com · 30 jun

Ecopetrol (EC) Stock Drops Despite Market Gains: Important Facts to Note

Ecopetrol (EC) concluded the recent trading session at $14.24, signifying a -2.2% move from its prior day's close.

zacks.com · 29 jun

Here is What to Know Beyond Why Ecopetrol S.A. (EC) is a Trending Stock

Ecopetrol (EC) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

gurufocus.com · 26 jun

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positi

zacks.com · 24 jun

Ecopetrol (EC) Dips More Than Broader Market: What You Should Know

The latest trading day saw Ecopetrol (EC) settling at $14.59, representing a -5.93% change from its previous close.

gurufocus.com · 23 jun

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

AbbVie Announces European Commission Approval of SKYRIZIÂ (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaqu

prnewswire.com · 23 jun

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

SKYRIZI ® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis 1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support weight-based dosing for patients weighing less than 40 kg 1 Nearly a third of people living with psoriasis develop symptoms before the age of 18, often getting lesions on highly visible areas 2,3 NORTH CHICAGO, Ill., June 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved SKYRIZI® (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy.

zacks.com · 22 jun

Ecopetrol (EC) Suffers a Larger Drop Than the General Market: Key Insights

In the most recent trading session, Ecopetrol (EC) closed at $16.25, indicating a -1.99% shift from the previous trading day.